Foundayo’s EU backing, Enspryng for TED, Gilead’s masked TCE deal, FDA’s rare disease reset, and Bausch + Lomb’s new interim CEO — explained.
|Articles|January 13, 2022
OKRA.ai Extends Collaboration with Bristol Myers Squibb
Advertisement
OKRA.ai, a provider of Artificial Intelligence (AI) driven analytics for global life sciences, today announced that it is extending its collaboration with Bristol Myers Squibb to leverage OKRA’s AI Technology to support future customer engagement. This collaboration, which started in the UK in 2018 has proven to be very successful in bringing together multiple data sources and generating intelligent insights for commercial teams whilst delivering unparalleled levels of automation for the company. In 2021 OKRA.ai and Bristol Myers Squibb expanded use of the system to new markets and will continue to work together and explore further expansion opportunities in 2022.
Read more about the collaboration
Advertisement
Related to this article
Incubate’s John Stanford on why MFN deals are voluntary in name only — and why the leverage looks a lot like the IRA’s 95% excise tax.
Lilly’s Foundayo receives a positive CHMP opinion for obesity and type 2 diabetes — putting the oral GLP-1 pill on course for EU approval.
The interleukin-6 receptor inhibitor gains a second indication, though one of two phase 3 trials missed its primary endpoint.
European regulators are increasing pressure on clinical trial sponsors to report study results on time, rolling out new monitoring, reminders and guidance as patient advocates welcome the progress but question whether stronger oversight and enforcement will follow.
Why “we’re safe” is the most dangerous assumption in medical benefit commercialization.
Fox Rothschild's Mark Wagner on why drug shortages are so hard to fix — from the definition gap to API dependency to three-year site approvals.
Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.
Advertisement
Advertisement
Trending on PharmExec
1
The Bubble You Don’t Know You’re In: A Three-Part Series on The Medical Benefit Bubble
2
FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease
3
EMA Panel Backs Lilly’s Foundayo for Obesity and Type 2 Diabetes in Europe
4
Is Participation in MFN Voluntary?
5